Apparatus for infusing liquid to a body

Information

  • Patent Grant
  • 8708961
  • Patent Number
    8,708,961
  • Date Filed
    Monday, January 28, 2008
    17 years ago
  • Date Issued
    Tuesday, April 29, 2014
    10 years ago
Abstract
An infusion device having a housing with a reusable control portion and an expendable reservoir portion includes a precise drive for an infusion pump. The drive includes a piezoelectric bender assembly, a limiter and at least one contact stop. The piezoelectric bender assembly includes a cantilevered piezoelectric bender having an member of predetermined thickness fixed to move with the second end. A limiter of dimensionally stable material including a gap and at least a first mounting hole extending to the gap. The member of predetermined thickness extends into the gap. A first contact stop is positioned in the gap to define a critical gap distance limiting movement of the member of predetermined thickness in the gap. A base has a mounting surface, a port through the base and extending to the mounting surface. The port includes a first length having a smaller diameter at the mounting surface and a second length displaced from the mounting surface and having a larger diameter. A rigid cannula extends from the base through the port. The rigid cannula has a diameter smaller than the smaller diameter of the port, and the first length of the port has an annular open gap for lateral or pivotal movement of the rigid cannula. A mount of elastomeric material in the length having the larger diameter mounts the rigid cannula. The cannula includes hydrogel material in a desiccated state coating the surface of the cannula, including the beveled end, which rehydrates upon placement in the patient.
Description
BACKGROUND OF THE INVENTIONS

The field of the present invention is infusion systems.


Today, diabetes is understood to be reaching epidemic proportions in the United States. It remains as a worldwide problem as well. Diabetes brings with it a host of medical problems which are aggravated by conventional medicament dosage schemes. Traditional shots and the like are intermittent which can induce a cyclical plethora and paucity of medicament, typically insulin. Recent efforts have been undertaken to eliminate such harmful cyclical variations through continuous administration of medicament. Additionally, devices and controls have been designed to provide both a basal rate for sustained infusion and periodic boluses to accommodate the ingestion of carbohydrates. With these advantageous capabilities, enhanced designs taking into account considerations regarding cost, portability, longevity and accuracy of dispensation remain of interest.


A wide variety of prior systems having applicable components and processes exist. Reference is made to U.S. Pat. Nos. 4,898,578; 5,205,819; 5,630,710; 6,645,142; 6,852,104; and 7,018,360. Reference is also made to U.S. Patent Publications Nos. 2002/0029776; 2003/0032867; 2003/0163088; 2004/0220551; and 2005/0137573. The disclosures of the foregoing patents and patent publications are incorporated herein by reference.


In addition to the infusion of insulin for diabetes, infusion is useful for other purposes in bodies of both humans and animals. The types of liquids that can be delivered include, but are not limited to, insulin, antibiotics, nutritional fluids, total parenteral nutrition or TPN, analgesics, morphine, hormones or hormonal drugs, gene therapy drugs, anticoagulants, analgesics, cardiovascular medications, AZT and chemotherapeutics. The types of medical conditions treatable by infusion include, but are not limited to, diabetes, cardiovascular disease, pain, chronic pain, cancer, AIDS, neurological diseases, Alzheimer's Disease, ALS, Hepatitis, Parkinson's Disease or spasticity.


Infused patients have increased mobility with portable infusion dispensing systems while achieving a more frequent or continuous dosing. Such systems have the potential for regulating dosing responsive to near term need and conditions, such as the intake of carbohydrates in the case of diabetes. Control of the dispensing process to achieve accurate dosing is a fundamental design criteria for such devices. Various approaches have been used to control pump parameters and flow with piezoelectric mechanisms. U.S. Pat. No. 6,986,649 uses valve control based on pressure. U.S. Pat. No. 7,258,253 uses a restrictive orifice. U.S. Pat. No. 7,290,993 uses electronic wave form control. The disclosures of these patents are incorporated herein by reference. Control and monitoring of piezoelectric systems accurately enough for infusion demands more than electronic input and needs performance feedback. Simple, reliable and inexpensive miniaturized systems not having expensive critical components and system complications remain advantageous.


Also of consideration with portable infusion dispensing systems is patient comfort. Such systems frequently require subcutaneous cannula. The solution has been to make the cannula of flexible material and use a rigid sharp pin through the cannula to place the device, then withdrawing the pin. Rigid cannula are less complicated to place but can induce discomfort with patient movement.


SUMMARY OF THE INVENTIONS

The present inventions are directed to apparatus for infusing liquid to a body. A system contemplates the employment of an infusion device including a piezoelectric driven pump. A rigid cannula is separately contemplated.


In a first aspect of the present invention, an infusion device includes a housing with a control portion and a reservoir portion with the two portions separable. Being separable, the more costly components can be reused, thereby reducing long term costs to the user.


The infusion device further includes a precise drive in the first aspect of the present invention. This drive includes a piezoelectric bender assembly, a limiter and a resilient device cooperating together to provide precise reciprocal motion. The piezoelectric bender has a first end fixed relative to the control portion, a second end movable relative to the first end and a member of predetermined thickness fixed to move with the second end. Through repeatedly electrifying the piezoelectric bender, precise reciprocal motion is achieved.


The limiter is of dimensionally stable material and includes a gap in the first aspect of the present invention. The member of predetermined thickness extends into the gap to define a stroke gap equal to the limiter gap less the predetermined thickness. The resilient device is engaged to move with the second end of the piezoelectric bender assembly. The resilient device acts in opposition to the bender assembly with the bender assembly exhibiting greater force than the resilient device when the bender assembly is electrified.


The resilient device has a resilient stroke greater than the stroke gap. This accommodates variations in the positioning of the control portion and the reservoir portion together. The member of the piezoelectric bender assembly is capable of a stroke driven by the piezoelectric bender which is greater than the stroke gap allowed by the limiter. This accommodates variations in the positioning of the piezoelectric bender relative to the control portion. With the member of predetermined thickness and the dimensionally stable limiter gap, the stroke gap can be precisely defined even with variations in substantially all other dimensions. As a result, assembly and use can be less precise without loss of precision in volumetric infusion.


A pump is engaged to move with the above resilient device during the stroke of the piezoelectric bender. The piezoelectric bender assembly and the limiter are mounted in the control portion for reuse. The resilient device and the pump are in the disposable reservoir portion to properly allocate expensive components for reuse and inexpensive components for disposal.


In a second separate aspect of the present inventions, an infusion system includes a precise drive for infusion. A piezoelectric bender assembly employs a piezoelectric cantilevered bender with one end fixed relative to the pump and the other end movable. A member of predetermined thickness is fixed to move with the free end. The member of predetermined thickness extends into the gap defined by a limiter of dimensionally stable material. One or more contact stops are positionable at a critical distance across the gap to limit the movement of the member of predetermined thickness. These contact stops can be precisely located and fixed in place to afford a stable stroke to the infusion pump with the only criticality being the gap defined by the limiter, including one or more contact stops.


In a third separate aspect of the present inventions, a precise drive for an infusion pump includes a piezoelectric bender assembly having a cantilevered bender with an member of predetermined thickness fixed to move with the free end of the bender. Contact stops are positionable and fixed at a critical distance apart to define a gap for the limiter. These contact stops input the strokes of the bender to accumulate volume pumped, provide feedback control and the like.


In a fourth separate aspect of the present inventions, an infusion device includes a base having a mounting surface. A port through the base extends to the mounting surface which has two lengths of different diameters. The length of smaller diameter extend to the mounting surface. A mount of elastomeric material is located in the length of larger diameter with the rigid cannula mounted therein. The length of smaller diameter has an annular open gap for lateral or pivotal movement of the rigid cannula. Through this mounting, discomfort associated with a rigid cannula is assuaged.


In a fifth separate aspect of the present invention, a system for infusing liquid to a body includes an infusion device having a source of infusion fluid, a delivery port to the body, a metering element coupled between the source of infusion fluid and the delivery port, a controller capable of programmable infusion rate and time sequences and a wireless communication device at the controller. The system further includes a remote control having a counter, an input to the counter and a wireless communication device for transmitting the input in the counter. The wireless communication devices provide a wireless link using a local area communication standard. The controller is capable of programming an infusion rate and time sequence to dispense a bolus of a volume corresponding to the input in the counter. The remote control provides mobility to a patient with no more than a keychain fob or pendant to accommodate a need for near term additional medication.


In a sixth separate aspect of the present invention, a system for infusing liquid to a body includes an infusion device having a source of infusion fluid, a delivery port to the body, a metering element coupled between the source of infusion fluid and the delivery port, a controller capable of programmable infusion rate and time sequences and a wireless communication device at the controller. The system further includes a remote control having a program for controlling the programmable infusion rate and time sequences and a portable communication link for loading the program on a computer for generating commands for the controller. Through the advantage of small electronic devices capable of being used as peripherals to almost any computer, a program for modifying the controller can be loaded on equipment easily employed by anyone with a modicum of computer literacy. Again, mobility is enhanced for the patient. With capability on the computer, direct transmission to the controller can be accomplished. Where that is not the case, the remote control can transmit reprogramming to the controller.


In a seventh separate aspect of the present inventions, combinations of these separate aspects are contemplated to further advantage.


Accordingly, it is an object of the present invention to provide improved infusion systems. Other and further objects and advantages will appear hereinafter.





DESCRIPTION OF THE DRAWINGS


FIG. 1 is a plan view of the infusion device.



FIG. 2 is an end view of the infusion device.



FIG. 3 is a cross-sectional elevation of FIG. 1.



FIG. 4 is a cross-sectional elevation of FIG. 1.



FIG. 4A is the cross-sectional elevation of FIG. 4 in greater detail.



FIG. 5 is a perspective view of the infusion device with the cover removed.



FIG. 5A is a cross-sectional elevation detail taken through the limiter.



FIG. 6 is a perspective view of the thin wall reservoir.



FIG. 7 is a cross-sectional elevation of a first mount of the cannula in the base of the infusion device.



FIG. 8 is a cross-sectional elevation of a second mount of the cannula in the base of the infusion device.



FIG. 9 is a cross-sectional elevation of a third mount of the cannula in the base of the infusion device.



FIG. 10 is a cross-sectional elevation of a fourth mount of the cannula in the base of the infusion device.



FIG. 11 is a plan view of an infusion device with a remote cannula.



FIG. 12 is a section view of the infusion device of FIG. 11.



FIG. 13 is a front view of a remote control.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Turning in detail to a preferred embodiment of a system for infusing liquid to a body, the systems presented in U.S. patent application Ser. No. 11/548,238, filed Oct. 10, 2006, U.S. patent application Ser. No. 11/618,682, filed Dec. 29, 2007, U.S. Provisional Application No. 60/991,145, filed Nov. 29, 2007 and U.S. Provisional Application No. 60/992,243, filed Nov. 29, 2007 are contemplated for employment with this invention and the disclosures are incorporated herein by reference.


An infusion device, generally designated 10, includes a somewhat truncated oblong housing 12 with a preferably low profile and a flat base. Other shapes are possible and the base may have some concavity for conformance to a body shape. The housing 12 is divided into a control portion 14 and a reservoir portion 16. The control portion 14 is intended to be used for a number of infusions. The reservoir portion 16 is intended to be expended after one use. To this end, the control portion 14 and the reservoir portion 16 are separable. A second control portion 14 may complete the set for the purpose of recharging one control portion 14 while using the other. Under such circumstances, the control portions preferably have independent electronic identities such that remote equipment can distinguish between controllers but can also reference cooperation as being employed by the same patient.


The control portion 14 has a cover 18 with a flat panel and outwardly inclined sides. The cover 18 is bonded to a panel 24 unless the configuration includes a non-rechargeable battery which requires opening of the case. If non-rechargeable, a separate compartment with a separate door is advantageous even though the battery compartment may remain as part of the control portion. If rechargeable, charging may occur with external sealed contacts or through induction. The panel 24 continues the outwardly inclined sides about its periphery and additionally includes a depending flange 26 to engage the reservoir portion 16. The control portion 14 is fully sealed against water intrusion except for one or more access holes through the panel 24 inwardly of the depending flange 26. To avoid a buildup from battery out-gassing, a hydrophobic, gas permeable barrier may be present in a small port through the housing. A control cavity 28 is created by the cover 18 and the panel 24.


The reservoir portion 16 includes a reservoir cover 30 and a base 32. The reservoir cover 30 includes a depending flange 34 which fits within a peripheral flange 36 extending upwardly from the base 32. The depending flange 34 and peripheral flange 36 create a channel 38′ about the reservoir portion 16 to receive the depending flange 26 of the control portion 14. This mating of the control portion 14 and the reservoir portion 16 through the positioning of the depending flange 26 in the channel 38 is preferably constructed to remain locked together during use of the infusion device 10. A ridge and groove engagement may be employed to create a physical overlap requiring resilient deformation of one part to achieve extraction of the control portion 14 from the reservoir portion 16. Other mechanical means can be used as well.


To complete the profile of the housing 12, an overmold skirt 40 affixed to the peripheral flange 36 extends fully about the housing 12. The skirt 40 is similarly outwardly inclined to provide an overall profile which will not engage clothing and the like with activity of the patient.


The reservoir portion 16 defines a cavity between the reservoir cover 30 and the base 32. This cavity 42 includes a thin wall reservoir 44 which is illustrated in FIG. 6 in its fully inflated state which provides a source of infusion fluid. This reservoir 44 is able to collapse as liquid is dispensed therefrom. A cavity 46 in the thin wall reservoir 44 accommodates a pump, described below. A port 48 allows a charging of the reservoir 44. A plug 50 closes the port 48 as well as a port 52 open through the reservoir cover 30.


The cavity 42 of the reservoir portion 16 allows the thin wall reservoir 44 to contract as liquid is expended from the reservoir. The intent is to have the reservoir 44 filled with liquid without any gas or air and to keep it that way as the liquid is expended. To allow this, some venting into the cavity 46, outwardly of the thin wall reservoir 44, enables this contraction. Component fit may allow for such venting or separate hole through the body of the reservoir portion 16 may be specifically employed.


A pump, acting as a metering element and generally designated 54, is arranged within the reservoir portion 16 in the cavity 46 formed by the thin wall reservoir 44. The pump 54 includes a pump body 56 having a cylinder 58 open toward the control portion 14. The cylinder 58 includes a head portion of smaller diameter with an intake port 62 and an exhaust port 64 in communication therewith. The two ports 62, 64 are controlled through check valves 66, 68 defined by spring biased balls. The intake check valve 66 allows liquid to flow through the intake port 62 when the pressure differential between the reservoir 44 and the cylinder 58 is in the cylinder 58. The exhaust check valve 68 is opened when the pressure in the cylinder 58 increases above that beyond the exhaust port 64. A positive displacement element, in this embodiment a piston 70, is slidably arranged in the cylinder 58 to effect a pumping action. A piston seal 72 prevents leakage around the piston 70. A filter 74 allows liquid capillary flow therethrough while excluding air and other gases from entering the intake port 62. To overcome blockage of the filter 74 by a bubble of air, a thin tube 75 extends into the thin wall reservoir 44 from the filter 74 to beyond any bubble of a size likely to cover the filter 74 in order that liquid flow may be drawn through the thin tube. A tube 76 extends from the exhaust port 64 toward the center of the housing 12 to direct a charge of medicament to the patient.


A mounting hole 78 extends through the reservoir cover 30 to receive a resilient device which, in this embodiment, is a membrane spring 80. The membrane spring 80 is fixed to the reservoir cover 30 about its periphery. The membrane spring 80 includes a central portion with a cavity 82 to receive a boss 84 on the piston 70. The piston 70 is fixed to this central portion to move with the center of the membrane spring 80 in the cylinder 58.


The base 32 of the reservoir portion 16 defines a mounting surface with adhesive for retention on the patient. A port 86 extends through the base 32 at approximately the geometric center thereof.


In the first embodiment, the tube 76 is shown to be bent at a 90-degree angle to additionally form a cannula 88 as the ultimate delivery port to the body. The tube may conveniently be stainless steel or initial. The cannula 88 is preferably coated with a hydrogel which is retained in a desiccated state until insertion. This coating extends over the sharpened beveled end of the cannula with the lumen cleared. Once in place, the hydrogel swells when in contact with interstitial fluid to provide softer relief around the hard cannula 88. The hydrogel contemplated is in the nature of soft contact lenses. To provide greater comfort to the patient, four cannula embodiments are illustrated in FIGS. 7 through 10. In these embodiments, the cannula 88 is in communication with the tube 76 through a flexible elbow 90 rather than a bend in the tubing.


In each of these embodiments, the base 32 is shown to be laminated at least around the port 86 with an inner layer 92. The employment of this inner layer 92 allows for placement and capture of a mount 94 of elastomeric material. In each instance, the base 32 includes a port 86 which extends through to the mounting surface of the base. This port 86 has two lengths of differing diameter. The first length 96 extending to the mounting surface has a smaller diameter while the second length 98, displaced from the mounting surface, has a larger diameter. In all cases, there is an annular gap 100 outwardly of the cannula 88. This gap allows for angular movement and lateral movement of the cannula 88 relative to the base 32 without constraint from the periphery of the port 86.


The mounts 94 are unique in each of FIGS. 7 through 10. The mount 94a includes a disk 102 slidable within a cylindrical cavity forming the second length 98 of the port 86. The mount 94a is shown to include a smaller cylindrical disk 104 integral with the disk 102 which extends into the first length 96. The first length 96 is expanded in diameter to accommodate the disk 104 and retain the ability to define the annular gap 100. Thus, lateral and pivotal movement of the cannula 88 is possible with the mount 94a of FIG. 7, the material of the mount 94a being elastomeric.


In FIG. 8, the annular gap 100 is defined by the first length 96 and the cannula 88 of smaller diameter. An O-ring 94b is employed in the second length 98 about the cannula 88 to again allow for lateral and angular movement of the cannula 88 relative to the base 32.


In FIG. 9, a modified mount 94c is shown in an appropriate second length 98 of larger diameter. This mount 94c may include an interior cavity of gel rather than being solid elastomer in order to further accommodate lateral and angular movement of the cannula 88 within the port 86.


Finally, FIG. 10 illustrates a mount 94d showing rotational movement of the cannula 88 without relying on mounting resilience. In this instance, the mount 94d is spherical within a spherical portion of the port 86. In all instances, the mount 94 resists the longitudinal motion of the cannula 88 therethrough to ensure full placement. The mounts 94 of FIGS. 7 and 9 can also be configured to allow longitudinal play of the cannula 88 without longitudinal movement of the cannula 88 through the mount 94.


Turning to the control portion 14, the control cavity 28 within the cover 18 and panel 24 provides room for a battery 106 and an electronics package 108. The electronics package 108 is powered by the battery 106 and includes a chip as a controller for control of pumping within the device 10. The electronics package 108 may also include a communication device, which is at minimum a wireless receiver and more preferably a transceiver. In this disclosure, the phrase “communication device” is employed to identify a transmitter, receiver or transceiver, as most appropriately understood from use. Other components such as employed in U.S. patent application Ser. No. 11/548,238 filed Oct. 10, 2006 are also contemplated.


A piezoelectric bender assembly, generally designated 110, is located between the battery 106 and the electronics package 108. The assembly 110 includes a cantilevered piezoelectric structural bender 112. At a first end of the bender 112, a mount 114 clamps the bender in combination with the panel 24 to maintain that end of the bender 112 fixed relative to the overall pump. The bender 112 is typically of bimetal construction with one layer powering the bender by being electrified to move the free end of the bender in one direction toward the membrane spring 80. The membrane spring 80 then restores the bender to its first position upon terminating the charge to the bender 112.


A bender tip 116 at the free end of the bender 112 is a block stably affixed to the bender 112. This tip 116 includes a finger 118 extending from one face of the bender against the center portion of the membrane spring 80. To engage the membrane spring 80, the finger 118 extends through the panel 24 at an opening 120. Additional holes 122 are shown through the panel 24 for leads to devices for sensing stroke. The bender tip 116 also covers the end of the piezoelectric bender 112. This tip 116 may be of dimensionally stable ceramic to insure continued calibration and minimal wear on reusable parts.


A member 124 extends from one edge of the bender 112 and has a specific thickness as measured in the direction of motion of the bender 112. The specific thickness of the member 124 may be fabricated to a specific value through machining or other process or may be accurately measured and later accommodated to account for the specific thickness measured. The member 124 may be of dimensionally stable ceramic as well.


A limiter 126 is affixed to the panel 24 and located within the control cavity 28. The limiter 126 is also of dimensionally stable material such as ceramic and includes a gap between two plates 128, 130. The member 124 extends to between the plates 128, 130 such that the motion of the bender 112 will be toward and away from alternate plates 128, 130 with each stroke and to define a stroke gap equal to the limiter gap less the predetermined thickness.


In the illustrated embodiment, each of the plates 128, 130 has a mounting hole 132, 134. These mounting holes 132, 134 are conveniently coaxial and are to either side of the gap defined by the plates 128, 130. They receive and affix contact stops 136, 138, respectively, through placement and bonding. Each of the stops 136, 138 allows a more precise location of one side of the gap defined between the plates 128, 130. With the employment of two holes 132, 134 and two stops 136, 138, both the size of the gap and the location of the gap in the direction of bender actuation can be controlled.


The size of the gap provides a specific stroke limit to the bender 112. The stroke of the bender 112 at the member 124 will then be the size of the precise gap defined by the contact stops 136, 138 less the thickness of the portion of the member 124 which is directly between the stops 136, 138. As a result, if the member 124 is of a predefined specific thickness, the gap between the contact stops 136, 138 can also be predefined. If the portion of the member 124 between the contact stops 136, 138 is of a predetermined but not predefined thickness, the contact stops 136, 138 must accommodate the intended stroke plus or minus the variation in the thickness of the member 124.


The need for a precise control of stroke is illustrated by an example. An appropriate single stroke dosage for U100 insulin is 0.05 units (5×10−4 ml.) having a weight of 0.00055 grams. Given the scale of the overall infusion device and resulting cylinder and piston size, the stroke which will give this single stroke dosage is on the order of 0.0050 of an inch, or 127 microns. Varying the bore of the cylinder 58 can change the appropriate stroke length to a small extent but not enough that a very precise ten percent overall tolerance of five ten thousands of an inch could vary significantly.


To achieve an appropriate stroke for the bender 112 without expensive requirements for close tolerance parts, the member 124 is either machined to a specific thickness or measured accurately. The limiter 126 is then gapped by locating the control stops 136, 138 in the mounting holes 132, 134 and placing a block of appropriate thickness between the stops 136, 138. The thickness of the gapping block is the appropriate stroke length of the bender 112 plus the thickness of the member 124.


The ability to place the stops 136, 138 for location of the gap in the direction of bender actuation is advantageous such that the bender assembly 110 need not be positioned relative to the gap with great precision. The cantilevered piezoelectric structural bender 112 is to be placed relative to the precise gap to reliably operate in a range of strong bending force. It also is to be placed relative to the precise gap to impose an appropriate pretension on the membrane spring 80. The block used to precisely size the gap between the stops 136, 138 is placed relative to the location of the member 124 on the inner panel 24 to achieve these conditions.


The range through which the bender 112 exhibits strong bending force and the range through which the membrane spring 80 provides adequate restoring force and adequate preload on the bender 112 are accommodated firstly through design selection of the cantilevered piezoelectric structural bender 112 and of the membrane spring 80. Such selections are made so that the precise gap size is sufficiently smaller than the operative ranges of the bender 112 and the resilient membrane spring 80 to allow an acceptable placement tolerance for the bender 112. With an acceptable placement tolerance for the bender 112, only one hole 134 with one contact stop 138 may be employed in precise relationship with one plate 128 to define a precise gap for an appropriate pump stroke.


The contact stop 136 facing toward the membrane spring 80 when the device is assembled is appropriately arranged such that the membrane spring 80 retains some tension imposed by the finger 118 when the member 124 is against the contact stop 136. The selection of an appropriate length finger 118 is also to be considered to achieve this condition. By retaining some tension in the membrane spring 80, force remains to move the bender 112 through a full intake stroke. Additionally, having a sufficient amount of pretension in the membrane spring 80 accommodates the variations in placement of the control portion 14 with the reservoir portion.


The contact stop 138 facing away from the membrane spring 80 when the device is assembled is then positioned based on the foregoing gap requirements. The bender 112 is to be arranged and constructed with such capability that it will forcefully actuate through the stroke from the contact stop 136 to the contact stop 138. Indeed, it is appropriate for the bender 112 to have the capability when energized to move beyond the contact stop 138. In this way, a full stroke is assured between the contact stops 136, 138.


The contact stop 138 may include a device on or in the contact surface to sense recognition of the member 124. The sensor may sense proximity, complete a circuit or otherwise recognize the presence of the member 124. The member 124 may also have a sensor, a target or conductivity to allow recognition with the contact 138 of stroke completion. The data provided may be employed to de-energize the piezoelectric bender to save battery power and/or to count strokes. The contact stop 136 may also include such sensing as an assurance that the device is operating through full strokes.


In operation, the infusion device is configured as one or two control portions 14 and multiple reservoir portions 16. Each control portion 14 is reusable and potentially rechargeable through induction or external contacts. A second control portion 14 would allow recharging remotely from the patient without the need to suspend infusion. Each reservoir portion 16 operates to infuse a patent for up to seventy two hours. The patient would assemble the control portion 14 with one of the reservoir portions 16 for use.


In the device of FIGS. 1-10, a plasticized sheet (not shown) is remove from the adhesive on the underside of the base 32 and the cannula 88 is exposed through the removal of a protective cover (not shown). The infusion device 10 would then be applied, either manually or through the use of an insertion device. If necessary, additional tape or bandaging to retain the device in place may be employed. In the embodiment of FIGS. 11 and 12, a remote port assembly 140 coupled with the infusion device 10 is shown. By using a remote port assembly 140, an inserter may be employed to position the cannula 88 without manual insertion by the patient. Such devices are disclosed in U.S. Pat. Nos. 6,926,694; 6,991,619; 6,991,620; 7,022,108; 7,128,730, the disclosures of which are incorporated herein by reference. A tube 142 extends from the infusion device 10 to couple with a flexible tube 144, which in turn is coupled with the remote port assembly 140.


Activation of the controller of the electronics package 108 may be through schemes set forth in the disclosures incorporated herein by reference. Taps on the infusion device 10 can activate the controller 108. Control and communication through input through a cell phone or other electronic device capable of transmitting a message to the controller 108 can then be used to regulate dosage and bolus administrations, as needed. Alternatively, a dedicated and elementary remote control 146 can be employed for fully mobile access.


The remote control 146 preferably employs simple controls to avoid error but any number of features can be added to enhance user convenience. IR or a local area RF communication standard could be used to communicate. As a bolus is typically needed with the taking of food or drink, the remote control 146 is directed to that event in its most elemental form. Turning on the remote control 146 can be accomplished as in many personal devices by pushing any button. A bolus depends in magnitude on the amount of carbohydrates to be ingested and, consequently, needs volume control. A counter including a count-up button 148 and a count-down button 150 can be used to provide input to the remote control 146 to select a volume. Alternatively, a single toggle could be employed. A small LCD counter screen 152 can verify the count. A send button 154 can then transmit the count, representing a bolus volume, to the controller 108. These buttons can be recessed or covered with a hinged guard to protect against the sending of unintended signals to the controller 108. The control can be deactivated simply through a time delay when no button is pushed. Preferably, the signal transmitted includes identity information as well as bolus volume so that the controller 146 can verify that the signal is genuine. The remote 146 preferably can also be capable of receiving a return verification from the controller 108. The remote 146 can most conveniently be a keychain fob or pendent carried by the patient.


To provide more extensive mobility, the remote control 146 can additionally or alternatively include a memory with a program for controlling programmable infusion rate and time sequences in the controller 108. This could include commands regarding basal rates as well as boluses. A portable communication link including a communication device or a USB port 156 with a cable 158 or configured as a memory stick, as examples, can communicate universally with accessible computers for loading the program onto such a computer. The computer can then be used for generating or amending commands to the controller 108. The commands generated can then be communicated to the controller 108 either directly from the computer or through the remote control 146. Identification of the remote control 146 could also be transmitted to the computer to insure controller access.


Once activated with control instructions from one of the foregoing means or through preloading of the controller 108, the electronics can initiate timed electrifying of the piezoelectric bender with feedback through one or more sensors on the contact stops 136, 138 and/or member 124. With pumping through the piston 70, medicament is drawn from the thin wall reservoir 44 and infused through the cannula 88 into the patient. As medicament is depleted from the thin wall reservoir 44, the reservoir collapses until it approaches exhaustion. An integration of flow through monitoring of the pump 54 determines when the reservoir is becoming exhausted and initiates an alarm to signal the need for a replacement reservoir. The process then can be repeated through the removal of the reservoir portion 16 and replacement of a new reservoir portion 16 with the control portion 14 to continue infusion.


Thus, an improved method and apparatus for the infusion of liquid to a body is disclosed. While embodiments and applications of this invention have been shown and described, it would be apparent to those skilled in the art that many more modifications are possible without departing from the inventive concepts herein. The invention, therefore is not to be restricted except in the spirit of the appended claims.

Claims
  • 1. An infusion device, comprising a housing including a control portion and a reservoir portion separable from the control portion;a precise drive including a piezoelectric bender assembly having a piezoelectric bender with a first end fixed relative to the control portion and a second end movable relative to the first end, a limiter fixed to the control portion including a first limiter end having a rest stop and a second limiter end having an actuator stop, the rest stop and the actuator stop defining a dimensionally stable limiter gap, the piezoelectric bender assembly extending into the limiter gap to define a stroke gap between the limiter and the piezoelectric bender assembly in the limiter gap, and a resilient device biased against the piezoelectric bender assembly to move with the piezoelectric bender assembly and having a resilient stroke greater than the stroke gap, the resilient device acting in opposition to the bender assembly with the bender assembly exhibiting greater force than the resilient device when the bender assembly is electrified, the piezoelectric bender assembly being capable of a stroke which is greater than the stroke gap allowed by the limiter;a pump including a cylinder and a piston capable of reciprocation in the cylinder, the piston engaged to move with the resilient device, the resilient device and the pump being in the reservoir portion.
  • 2. The infusion device of claim 1, the resilient device biasing the piezoelectric bender assembly forcefully against the rest stop in the limiter gap when the piezoelectric bender is not electrified, the piezoelectric bender assembly being forcefully driven against the actuation stop in the limiter gap when the piezoelectric bender is electrified.
  • 3. The infusion device of claim 2, the resilient device being a diaphragm having a periphery fixed relative to the reservoir portion and a central portion against which the piezoelectric bender assembly is in contact with the control portion and the reservoir portion assembled.
  • 4. The infusion device of claim 2, the piston being coupled with the central portion of the resilient device with the resilient device being between the piezoelectric bender assembly and the piston.
  • 5. The infusion device of claim 1, the piezoelectric bender assembly further having a member of predetermined thickness separately fabricated from the piezoelectric bender and affixed thereto, the member of predetermined thickness extending into the limiter gap, the stroke gap being equal to the limiter gap less the predetermined thickness.
  • 6. The infusion device of claim 5, the member of predetermined thickness being of the dimensionally stable material of the limiter, the dimensionally stable material being a ceramic.
  • 7. The infusion device of claim 1, the stroke gap being on the order of 0.0050 of an inch.
  • 8. The infusion device of claim 1, the limiter including a sensor capable of registering the contact of the piezoelectric bender assembly with the actuator stop when the piezoelectric bender is electrified.
  • 9. The infusion device of claim 1, the limiter having at least a first mounting hole extending to the gap and at least a first contact stop fixable in the at least first mounting hole at a position to define the limiter gap.
  • 10. The infusion device of claim 9, the at least first mounting hole being two mounting holes extending to the gap and the at least first contact stop being two contact stops fixable in the mounting holes, respectively, at positions to define the limiter gap.
  • 11. The infusion device of claim 9, the first contact stop and the bender assembly including sensor recognition of contact for sensing completion of a piezoelectric bender stroke.
  • 12. The infusion device of claim 1 further comprising a controller in the control portion in communication with the piezoelectric bender;a reservoir in the reservoir portion, the pump being in communication with the reservoir and engaged to move with the resilient device;a battery retained in the control portion in communication with the controller.
  • 13. The infusion device of claim 12 further comprising a wireless communication device at the controller;a dedicated remote control in the form of a fob or pendent including a counter, an input to the counter and a wireless communication device for transmitting the input in the counter, the wireless communication device and the dedicated remote control providing a wireless link, the controller programming an infusion rate and time sequence to dispense a bolus of a volume corresponding to the input in the counter.
  • 14. The infusion device of claim 1 further comprising an infusion outlet from the reservoir portion and coupled with the pump, the infusion outlet including a cannula extending perpendicularly from the housing.
  • 15. An infusion device, comprising a housing including a control portion and a reservoir portion separable from the control portion;a precise drive mounted in the control portion and including a piezoelectric bender assembly having a piezoelectric bender with a first end fixed to the control portion and a second end movable relative to the first end and a limiter including a first limiter end having a first stop and a second limiter end having a second stop, the first and second stops defining a dimensionally stable limiter gap there between, the limiter being fixed to the control portion, the piezoelectric bender assembly extending into the limiter gap to define a stroke gap between the limiter and the piezoelectric bender assembly in the limiter gap, the piezoelectric bender assembly being capable of a stroke which is greater than the stroke gap allowed by the limiter;a pump including a cylinder and a piston capable of reciprocation in the cylinder, the piston engaged to move with the piezoelectric bender assembly.
  • 16. The infusion device of claim 15, the piezoelectric bender assembly further having a member of predetermined thickness separately fabricated from the piezoelectric bender and affixed thereto, the member of predetermined thickness extending into the limiter gap, the stroke gap being equal to the limiter gap less the predetermined thickness.
  • 17. The infusion device of claim 15, the limiter including a sensor capable of registering the contact of the piezoelectric bender assembly with the limiter when the piezoelectric bender is electrified.
  • 18. The infusion device of claim 15, at least the first limiter end having a first mounting hole extending to the gap, the first stop including a first contact stop separate from the first limiter end and fixable in the first mounting hole at a position to define the limiter gap with the second stop.
  • 19. The infusion device of claim 18, the first contact stop and the bender assembly including sensor recognition of contact for sensing completion of a piezoelectric bender stroke.
  • 20. The infusion device of claim 15 further comprising an infusion outlet from the reservoir portion and coupled with the pump, the infusion outlet including a cannula extending perpendicularly from the housing.
  • 21. The infusion device of claim 15 further comprising an infusion outlet from the reservoir portion and coupled with the pump, the infusion outlet including a cannula extending perpendicularly from the housing.
  • 22. An infusion device, comprising a housing including a control portion and a reservoir portion separable from the control portion;a precise drive mounted in the control portion and including a piezoelectric bender assembly having a piezoelectric bender with a first end fixed to the control portion and a second end movable relative to the first end and a limiter including two limiter ends and two elements at the ends, respectively, defining a dimensionally stable limiter gap there between, the limiter being fixed to the control portion, the piezoelectric bender assembly extending into the limiter gap to define a stroke gap between the limiter and the piezoelectric bender assembly in the limiter gap, the piezoelectric bender assembly being capable of a stroke which is greater than the stroke gap allowed by the limiter;a pump mounted in the reservoir portion, the pump including a cylinder, a piston capable of reciprocation in the cylinder and engaged to move with the piezoelectric bender assembly, a resilient diaphragm having a periphery fixed relative to the reservoir portion and a central portion against which the piezoelectric bender assembly is in contact, the piston being attached to the central portion of the resilient diaphragm and extending away from the piezoelectric bender assembly.
  • 23. The infusion device of claim 22, the resilient diaphragm being biased against the piezoelectric bender assembly to move with the piezoelectric bender assembly and having a resilient stroke greater than the stroke gap, the resilient diaphragm biasing the piezoelectric bender assembly forcefully against one side of the limiter gap when the piezoelectric bender is not electrified, the piezoelectric bender assembly being forcefully driven against the other side of the limiter gap when the piezoelectric bender is electrified.
  • 24. The infusion device of claim 22, one of the two limiter ends having a mounting hole extending to the gap, one of the two elements defining a contact stop separate from the mounting hole and fixable therein at a position to define the limiter gap with the other element.
  • 25. The infusion device of claim 24, the contact stop and the bender assembly including sensor recognition of contact for sensing completion of a piezoelectric bender stroke.
US Referenced Citations (198)
Number Name Date Kind
4221219 Tucker Sep 1980 A
4231019 Junginger et al. Oct 1980 A
4373527 Fischell Feb 1983 A
4449893 Beckman et al. May 1984 A
4468221 Mayfield Aug 1984 A
4469481 Kobayashi Sep 1984 A
4565542 Berg Jan 1986 A
4596575 Rosenberg et al. Jun 1986 A
4650469 Berg et al. Mar 1987 A
4685903 Cable et al. Aug 1987 A
4734092 Millerd Mar 1988 A
4871351 Feingold Oct 1989 A
4886499 Cirelli et al. Dec 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4944659 Labbe et al. Jul 1990 A
5085562 van Lintel Feb 1992 A
5205819 Ross et al. Apr 1993 A
5219278 Van Lintel Jun 1993 A
5224843 Van Lintel Jul 1993 A
5271724 Van Lintel Dec 1993 A
5277556 VanLintel Jan 1994 A
5328460 Lord et al. Jul 1994 A
5338157 Blomquist Aug 1994 A
5376070 Purvis Dec 1994 A
5433710 Van Antwerp Jul 1995 A
5443508 Giampapa Aug 1995 A
5480386 Brohy et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5507737 Palmskog Apr 1996 A
5569186 Lord et al. Oct 1996 A
5569187 Kaiser Oct 1996 A
5575770 Melsky et al. Nov 1996 A
5582593 Hultman Dec 1996 A
5630710 Tune et al. May 1997 A
5637095 Nason et al. Jun 1997 A
5658250 Blomquist et al. Aug 1997 A
5665070 McPhee Sep 1997 A
5695473 Olsen Dec 1997 A
5707361 Slettenmark Jan 1998 A
5725363 Bustgens et al. Mar 1998 A
5759014 Van Lintel Jun 1998 A
5759015 Van Lintel et al. Jun 1998 A
5761782 Sager Jun 1998 A
5764159 Neftel Jun 1998 A
5773913 Casselden Jun 1998 A
5788669 Peterson Aug 1998 A
5798600 Sager et al. Aug 1998 A
5807375 Gross et al. Sep 1998 A
5810015 Flaherty Sep 1998 A
5848991 Gross et al. Dec 1998 A
5858005 Kriesel Jan 1999 A
5931814 Alex et al. Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5954058 Flaherty Sep 1999 A
5957890 Mann et al. Sep 1999 A
5957895 Sage et al. Sep 1999 A
5961492 Kriesel et al. Oct 1999 A
5997263 Van Lintel et al. Dec 1999 A
5997501 Gross et al. Dec 1999 A
6024340 Lazarus et al. Feb 2000 A
6106498 Friedli et al. Aug 2000 A
6174300 Kriesel et al. Jan 2001 B1
6237619 Maillefer et al. May 2001 B1
6248093 Moberg Jun 2001 B1
6259587 Sheldon et al. Jul 2001 B1
6309189 Rey-Mermet et al. Oct 2001 B1
6368079 Peters et al. Apr 2002 B2
6375638 Nason et al. Apr 2002 B2
6390791 Maillefer et al. May 2002 B1
6423035 Das et al. Jul 2002 B1
6428289 Lishanski et al. Aug 2002 B1
6458102 Mann et al. Oct 2002 B1
6461331 Van Antwerp Oct 2002 B1
6485461 Mason et al. Nov 2002 B1
6488652 Weijand et al. Dec 2002 B1
6581638 Frisch et al. Jun 2003 B2
6585695 Adair et al. Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6589299 Missling et al. Jul 2003 B2
6595756 Gray et al. Jul 2003 B2
6645142 Braig et al. Nov 2003 B2
6656148 Das et al. Dec 2003 B2
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6669669 Flaherty et al. Dec 2003 B2
6692457 Flaherty Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6716002 Higashino Apr 2004 B2
6719739 Verbeek et al. Apr 2004 B2
6723072 Flaherty et al. Apr 2004 B2
6740059 Flaherty May 2004 B2
6740072 Starkweather et al. May 2004 B2
6749587 Flaherty Jun 2004 B2
6752787 Causey et al. Jun 2004 B1
6768425 Flaherty et al. Jul 2004 B2
6770067 Lorenzen et al. Aug 2004 B2
6774437 Bryant et al. Aug 2004 B2
6809653 Mann et al. Oct 2004 B1
6827559 Peters et al. Dec 2004 B2
6827702 Lebel et al. Dec 2004 B2
6830558 Flaherty et al. Dec 2004 B2
6843782 Gross et al. Jan 2005 B2
6852104 Blomquist Feb 2005 B2
6878132 Kipfer Apr 2005 B2
6948918 Hansen Sep 2005 B2
6960192 Flaherty et al. Nov 2005 B1
6974437 Lebel et al. Dec 2005 B2
6986649 Dai et al. Jan 2006 B2
7005078 Van Lintel et al. Feb 2006 B2
7018360 Flaherty et al. Mar 2006 B2
7029455 Flaherty Apr 2006 B2
7040335 Ransom May 2006 B1
7052251 Nason et al. May 2006 B2
7107086 Reihl et al. Sep 2006 B2
7115111 Haindl Oct 2006 B2
7122005 Shusterman Oct 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7128730 Marano-Ford et al. Oct 2006 B2
7137964 Flaherty Nov 2006 B2
7141023 Diermann et al. Nov 2006 B2
7144384 Gorman et al. Dec 2006 B2
7179226 Crothall et al. Feb 2007 B2
7186236 Gibson et al. Mar 2007 B2
7193521 Moberg et al. Mar 2007 B2
7195609 Huegli Mar 2007 B2
7204823 Estes et al. Apr 2007 B2
7218968 Condie et al. May 2007 B2
7255690 Gray et al. Aug 2007 B2
7258253 Nicol et al. Aug 2007 B2
7268466 Rasmussen Sep 2007 B2
7275522 Beilharz et al. Oct 2007 B2
7284962 Blakey Oct 2007 B2
7287965 Vogeley et al. Oct 2007 B2
7290993 Vogeley et al. Nov 2007 B2
7291110 Sahatjian Nov 2007 B2
7297111 Iliff Nov 2007 B2
7300402 Iliff Nov 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7306560 Iliff Dec 2007 B2
20020029776 Blomquist Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20030014011 Robert Jan 2003 A1
20030055380 Flaherty Mar 2003 A1
20030163088 Blomquist Aug 2003 A1
20040078028 Flaherty et al. Apr 2004 A1
20040092873 Moberg May 2004 A1
20040116866 Gorman et al. Jun 2004 A1
20040158230 Hunn et al. Aug 2004 A1
20040204673 Flaherty Oct 2004 A1
20040220551 Flaherty et al. Nov 2004 A1
20040235446 Flaherty et al. Nov 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050021005 Flaherty et al. Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050043676 Remde et al. Feb 2005 A1
20050065464 Talbot et al. Mar 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050090808 Malave et al. Apr 2005 A1
20050137573 McLaughlin Jun 2005 A1
20050159708 Sidler Jul 2005 A1
20050171512 Flaherty Aug 2005 A1
20050177137 Kipler Aug 2005 A1
20050182366 Vogt et al. Aug 2005 A1
20050182391 Schiltges et al. Aug 2005 A1
20050197625 Haueter et al. Sep 2005 A1
20050215982 Malave et al. Sep 2005 A1
20050222645 Malave et al. Oct 2005 A1
20050238507 DiIanne et al. Oct 2005 A1
20050273080 Paul Dec 2005 A1
20060031094 Cohen et al. Feb 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060041229 Garibotto et al. Feb 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060074381 Malave et al. Apr 2006 A1
20060116664 Richter et al. Jun 2006 A1
20060131530 East Jun 2006 A1
20060137695 Hellwig et al. Jun 2006 A1
20060147325 Vogeley Jul 2006 A1
20060178633 Garibotto et al. Aug 2006 A1
20060282290 Flaherty et al. Dec 2006 A1
20070090321 Bork Apr 2007 A1
20070118405 Campbell et al. May 2007 A1
20070129688 Scheurer et al. Jun 2007 A1
20070181425 Kim Aug 2007 A1
20070219480 Kamen et al. Sep 2007 A1
20070233206 Frikart et al. Oct 2007 A1
20070251835 Mehta et al. Nov 2007 A1
20070253021 Mehta Nov 2007 A1
20070253380 Jollota et al. Nov 2007 A1
20070254593 Jollota et al. Nov 2007 A1
20070255116 Mehta et al. Nov 2007 A1
20070255126 Moberg et al. Nov 2007 A1
20070255250 Moberg et al. Nov 2007 A1
20070255348 Holtzclar Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20080086086 Field et al. Apr 2008 A1
20080119705 Patel et al. May 2008 A1
20080161754 Marano-Ford et al. Jul 2008 A1
Foreign Referenced Citations (1)
Number Date Country
1 837 787 Sep 2007 EP
Non-Patent Literature Citations (4)
Entry
Official Action mailed Jan. 8, 2009 in companion U.S. Appl. No. 11/618,682, filed Dec. 29, 2006.
PCT Application No. PCT/US2007/86835 filed Dec. 7, 2007.
U.S. Appl. No. 11/548,238, filed Oct. 10, 2006.
U.S. Appl. No. 11/618,682, filed Dec. 29, 2006.
Related Publications (1)
Number Date Country
20100331826 A1 Dec 2010 US